stock ticker hero image

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
August 13, 2026 4:26 am ET
Delayed at least 20 minutes

View stock information

Latest news, events, & financials

View all

  2Q26 MSD Earnings Announcement

  2Q26 MSD Other Financial Disclosures

  2Q26 Other Financial Disclosures (Excel)

  2Q26 Prepared Remarks

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline
Phase II programs
50+

Phase III programs
30+

Under review
5+

illustration of leadership speaking panel

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership
Split image showing a gloved hand holding a petri dish with greenish-blue microbial colonies on the left, and an artistic Earth covered in green foliage and blue oceans on the right

Sustainability

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Purpose for Progress Impact Report 2024/2025

Download our Sustainability financing documents

2023 Sustainability bond allocation report

2022 Sustainability bond allocation report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories
scientist working in a lab
Innovation

Our Q2 2026 financial results

MSD’s Q2 2026 results reflect continued strength in oncology and animal health, plus increasing contributions from launches. Our company announced Q2 worldwide sales of $16.6 billion. “We continued to make substantial progress across our business this quarter, driven by strong execution and growing contributions from new product launches,” said Rob Davis, chairman and CEO. “The […]

Read more
scientist wearing purple gloves and a white coat working in a lab
Innovation

Our Q1 2026 financial results

MSD’s Q1 2026 results reflect continued strength in oncology and animal health, plus increasing contributions from launches. Our company announced Q1 worldwide sales of $16.3 billion. “We are moving with speed to transform our portfolio to one with a diversified set of growth drivers across a broad set of therapeutic areas,” said Rob Davis, chairman […]

Read more
two scientists working in a lab
Innovation

Our Q4 and full-year 2025 financial results

MSD’s Q4 and full-year 2025 sales performance reflects strength across oncology and animal health, as well as increasing contributions from new launches. Our company announced Q4 worldwide sales of $16.4 billion. Full-year 2025 worldwide sales were $65.0 billion. “In 2025, we continued to advance leading-edge science to deliver transformative medicines and vaccines that are improving […]

Read more
Contact us banner image
For questions, please contact our team.

Contact investor relations

Phone icon +1 (732) 594-1468
Email icon Email our team